Payment overview · 2025
General Payments
$2,922.59
123 reported records · 29 companies
Healthcare provider profile · identity verified
Alexander Mora, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1225111941
Verified facts
What the public records show
CMS Open Payments records show Alexander Mora, M.D. received $2,922.59 in general payments during 2025 across 123 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Farxiga, Gemtesa, Ingrezza, Mounjaro, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Edarbyclor by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Horizant by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $493.52 | 16.9% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $371.86 | 12.7% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $296.90 | 10.2% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $257.49 | 8.8% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $198.52 | 6.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $153.90 | 5.3% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $120.63 | 4.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.41 | 4.0% | 5 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $109.19 | 3.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.55 | 3.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $93.03 | 3.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.45 | 2.0% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $52.71 | 1.8% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $51.17 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.80 | 1.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.19 | 1.6% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $40.93 | 1.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.26 | 1.4% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $39.00 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.19 | 1.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.08 | 1.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.99 | 1.1% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.44 | 1.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.50 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.88 | 0.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.50 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.59 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,922.59 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $493.52 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $309.62 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $240.55 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $219.40 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $219.40 | 12 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $198.52 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $193.22 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.86 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $120.63 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $115.41 | 5 | 2025 |
Source payment records
|
|||||
| Phasix Mesh Normalized: phasix mesh |
Device | Becton, Dickinson and Company | $109.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.55 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.51 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.24 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $53.71 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $52.71 | 3 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $51.17 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $51.17 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $51.17 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.80 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $45.19 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.99 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 253 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
137 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
253 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 172 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 466 | 139 |
| Alprazolam | Alprazolam | 296 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 107 |
| Celecoxib | Celecoxib | 283 | 117 |
| Metformin Hcl | Metformin Hcl | 281 | 102 |
| Losartan Potassium | Losartan Potassium | 268 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 75 |
| Carvedilol | Carvedilol | 258 | 71 |
| Mounjaro | Tirzepatide | 253 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 85 |
| Lisinopril | Lisinopril | 226 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 224 | 68 |
| Furosemide | Furosemide | 200 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 165 | 59 |
| Ozempic | Semaglutide | 162 | 38 |
| Gabapentin | Gabapentin | 156 | 57 |
| Ezetimibe | Ezetimibe | 154 | 50 |
| Finasteride | Finasteride | 151 | 48 |
| Temazepam | Temazepam | 148 | 41 |
| Nifedipine Er | Nifedipine | 145 | 47 |
| Vraylar | Cariprazine Hcl | 137 | 25 |
| Glimepiride | Glimepiride | 133 | 42 |
| Tramadol Hcl | Tramadol Hcl | 128 | 59 |
| Pregabalin | Pregabalin | 127 | 32 |
| Linzess | Linaclotide | 126 | 31 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 126 | 26 |
| Terbinafine Hcl | Terbinafine Hcl | 122 | 60 |
| Meloxicam | Meloxicam | 121 | 50 |
| Eliquis | Apixaban | 116 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 36 |
| Glipizide | Glipizide | 108 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 33 |
| Omeprazole | Omeprazole | 100 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 33 |
| Montelukast Sodium | Montelukast Sodium | 97 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 35 |
| Clonidine Hcl | Clonidine Hcl | 96 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 95 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 30 |
| Famotidine | Famotidine | 78 | 28 |
| Trazodone Hcl | Trazodone Hcl | 78 | 39 |
| Jardiance | Empagliflozin | 77 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 22 |
| Simvastatin | Simvastatin | 68 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 23 |
| Methocarbamol | Methocarbamol | 66 | 31 |
| Alogliptin | Alogliptin Benzoate | 63 | 18 |
| Clonidine | Clonidine | 60 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 59 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Azithromycin | Azithromycin | 56 | 44 |
| Farxiga | Dapagliflozin Propanediol | 56 | 24 |
| Buspirone Hcl | Buspirone Hcl | 54 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 41 |
| Ibuprofen | Ibuprofen | 54 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 18 |
| Clonazepam | Clonazepam | 51 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 50 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 29 |
| Fluconazole | Fluconazole | 48 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 16 |
| Nitroglycerin | Nitroglycerin | 47 | 29 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Levetiracetam | Levetiracetam | 43 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Trulicity | Dulaglutide | 42 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Prednisone | Prednisone | 39 | 33 |
| Belsomra | Suvorexant | 38 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 23 |
| Lamotrigine | Lamotrigine | 37 | 12 |
| Ramipril | Ramipril | 37 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Doxepin Hcl | Doxepin Hcl | 35 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 14 |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 19 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 12 |
| Cilostazol | Cilostazol | 32 | 15 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 19 |
| Buprenorphine | Buprenorphine | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 13 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 17 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lamotrigine Odt | Lamotrigine | 28 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Ingrezza | Valbenazine Tosylate | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 13 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 14 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Naproxen | Naproxen | 19 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 14 |
| Lithium Carbonate Er | Lithium Carbonate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 15 | suppressed |
| Horizant | Gabapentin Enacarbil | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Calcipotriene | Calcipotriene | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 12 | 11 |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,922.59 · 123 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, EDARBI, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Grastek, INGREZZA, KEVEYIS, KRISTALOSE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Odactra, Omnipod, PAXLOVID, PROLIA, Phasix Mesh, QULIPTA, QUTENZA, Qelbree, REPATHA, REXULTI, Ragwitek, Sunosi, The Cologuard Plus Collection Kit, VERQUVO, VOQUEZNA, VRAYLAR, XIFAXAN, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error